TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Go back to TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance| TG THERAP (NASDAQ: TGTX) | Delayed: 55.99 +0.01 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.98 | 52 Week High | $14.87 | |||
| Open | $55.99 | 52 Week Low | $4.90 | |||
| Day High | $55.99 | P/E | N/A | |||
| Day Low | $55.99 | EPS | $-0.67 | |||
| Volume | 9,872 | |||||

